New combo insulin shows promise for better daily glucose control in type 2 diabetes
NCT ID NCT06671587
First seen Mar 26, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study compares two injectable diabetes treatments—iGlarLixi (a combination insulin and GLP-1 drug) and Gla-100 (a standard insulin)—in Chinese adults with type 2 diabetes whose blood sugar is not well controlled with oral medications. About 678 participants will use a continuous glucose monitor for 20 weeks to see which treatment keeps blood sugar in a healthy range more of the time. The goal is to find a more effective option for daily diabetes management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2D) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 1560001
RECRUITINGBeijing, 100730, China
Conditions
Explore the condition pages connected to this study.